GlaxoSmithKline and Innoviva have won European approval for the novel triple therapy inhaler Trelegy Ellipta, offering a new treatment option for patients with Chronic Obstructive Pulmonary Disorder (COPD).
News
NICE waves through breast cancer drugs following price deals
The National Institute for Health and Care Excellence is backing routine NHS funding for Pfizer’s Ibrance and Novartis’ Kisqali to treat certain forms of breast cancer, after the firms agreed to provide them at a reduced price under the new process for appraising medicines.
Health bodies test digital interventions for diabetes
NHS England, Public Health England and Diabetes UK have teamed up with leading companies from the tech sector to test new digital approaches to fighting type II diabetes.
EU, US approvals for Faslodex combinations
AstraZeneca’s Faslodex has been cleared on both sides of the Atlantic for use in combination with a CDK4/6 inhibitor.
Bayer, Loxo link in $1.55bn cancer drugs deal
Bayer and Loxo Oncology have agreed to work together on the development and commercialisation of two novel cancer therapies, in a deal potentially worth more than $1.5 billion to the latter firm.
AZ’ Fasenra gets US nod for eosinophilic asthma
AstraZeneca’s biologic Fasenra has picked up its first global approval in the US as a treatment for severe, eosinophilic asthma, a difficult to treat form of the condition.
EU approves subcutaneous form of GSK’s Benlysta
A new subcutaneous formulation of GlaxoSmithKline’s Benlysta has been approved as an add-on therapy for certain in adults with the autoimmune disease systemic lupus erythematosus (SLE).
Boehringer bags first biosimilar approval in the EU
Boehringer Ingelheim has won its first biosimilar approval in Europe with authorisation of Cyltezo for a range of chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
Scotland approves three new meds for NHS use
The Scottish Medicines Consortium (SMC) has published new advice accepting three new medicines for use by NHS Scotland, offering patients new treatment options for soft tissue sarcoma, acromegaly and hepatitis C
EU PRIME status for Mereo’s brittle bone drug
London, UK-based Mereo BioPharma’s experimental drug targeting brittle bone disease has been designated PRIME status by the European Medicines Agency (EMA).
Leicester first UK city chosen for global diabetes initiative
Leicester is the first UK city to be chosen for the Novo Nordisk-led global initiative Cities Changing Diabetes, which aims to tackle the dramatic rise of type II diabetes in urban areas.
NICE turns down Shire’s Revestive for bowel condition
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for Shire’s Revestive as a treatment for short bowel syndrome (SBS).
MSD’s Prevymis approved for CMV prevention
MSD’s Prevymis has been green-lighted in the US to prevent cytomegalovirus infection and disease in at-risk adults who have received an allogeneic hematopoietic stem cell transplant (HSCT).
FDA clears first new hep B vaccine in 25 years
The US Food and Drug Administration is allowing onto the market the first new hepatitis B vaccine in more than 25 years with the approval of Dynavax’ Heplisav-B.
Bayer, Janssen’s Xarelto cuts risk of amputation, death
Two new analyses of data from the COMPASS trial show that Bayer and Janssen’s blood thinner Xarelto significant cut the amputation rate for patients with peripheral artery disease and also a 23 percent reduction in deaths in patients with coronary artery disease.
